{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:12:11Z","timestamp":1790856731074,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.bmc.2024.117881","type":"journal-article","created":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T23:28:02Z","timestamp":1723850882000},"page":"117881","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Exploring novel A2AAR antagonists: Design, synthesis, and evaluation of 2,6,9-trisubstituted purine derivatives as promising antifibrotic agents"],"prefix":"10.1016","volume":"112","author":[{"given":"Jingyang","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seojeong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seojeong","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seohui","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naeun","family":"Sheen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soobin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6256-3042","authenticated-orcid":false,"given":"Youngjoo","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0802-6398","authenticated-orcid":false,"given":"Jae-Sang","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2024.117881_b0005","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1177\/1535370219898141","article-title":"Mechanisms of liver fibrosis and its role in liver cancer","volume":"245","author":"Dhar","year":"2020","journal-title":"Exp Biol Med"},{"key":"10.1016\/j.bmc.2024.117881_b0010","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s13105-023-00954-4","article-title":"Metabolic dysfunction-associated fatty liver disease (MAFLD): an update of the recent advances in pharmacological treatment","volume":"79","author":"Sangro","year":"2023","journal-title":"J Physiol Biochem"},{"key":"10.1016\/j.bmc.2024.117881_b0015","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jhepr.2019.10.008","article-title":"Lifestyle modification in NAFLD\/NASH: facts and figures","volume":"1","author":"Hallsworth","year":"2019","journal-title":"JHEP Rep."},{"key":"10.1016\/j.bmc.2024.117881_b0020","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1055\/s-0035-1562942","article-title":"Diagnosis and assessment of NAFLD: definitions and histopathological classification","volume":"35","author":"Burt","year":"2015","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.bmc.2024.117881_b0025","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1053\/j.gastro.2014.07.056","article-title":"Pathological features of fatty liver disease","volume":"147","author":"Yeh","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bmc.2024.117881_b0030","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jhep.2010.04.031","article-title":"Hepatocellular ballooning in NASH","volume":"53","author":"Caldwell","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.bmc.2024.117881_b0035","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1111\/liv.15930","article-title":"The first MASH drug therapy on the horizon: current perspectives of resmetirom","volume":"44","author":"Petta","year":"2024","journal-title":"Liver Int"},{"key":"10.1016\/j.bmc.2024.117881_b0040","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/nri.2017.11","article-title":"Liver macrophages in tissue homeostasis and disease","volume":"17","author":"Krenkel","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.bmc.2024.117881_b0045","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1053\/j.gastro.2012.06.036","article-title":"Deactivation of hepatic stellate cells during liver fibrosis resolution in mice","volume":"143","author":"Troeger","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bmc.2024.117881_b0050","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1074\/jbc.275.4.2247","article-title":"Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury","volume":"275","author":"Friedman","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmc.2024.117881_b0055","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1038\/labinvest.2010.123","article-title":"Kupffer cells are associated with apoptosis, inflammation and fibrotic effects in hepatic fibrosis in rats","volume":"90","author":"Liu","year":"2010","journal-title":"Lab Invest"},{"key":"10.1016\/j.bmc.2024.117881_b0060","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1038\/cr.2009.73","article-title":"Lipid accumulation in hepatocytes induces fibrogenic activation of hepatic stellate cells","volume":"19","author":"Wobser","year":"2009","journal-title":"Cell Res"},{"key":"10.1016\/j.bmc.2024.117881_b0065","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/sj.bjp.0706812","article-title":"Adenosine A(2A) receptors play a role in the pathogenesis of hepatic cirrhosis","volume":"148","author":"Chan","year":"2006","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bmc.2024.117881_b0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/pr.110.003285","article-title":"International union of basic and clinical pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update","volume":"63","author":"Fredholm","year":"2011","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.bmc.2024.117881_b0075","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/nrc.2017.86","article-title":"Targeting immunosuppressive adenosine in cancer","volume":"17","author":"Vijayan","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bmc.2024.117881_b0080","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s002100000313","article-title":"Structure and function of adenosine receptors and their genes","volume":"362","author":"Fredholm","year":"2000","journal-title":"Naunyn Schmiedeb Arch Pharmacol"},{"key":"10.1016\/j.bmc.2024.117881_b0085","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1146\/annurev.immunol.22.012703.104731","article-title":"Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors","volume":"22","author":"Sitkovsky","year":"2004","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.bmc.2024.117881_b0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/cld.777","article-title":"Adenosinergic Signaling in Liver Fibrosis","volume":"14","author":"Tiwari-Heckler","year":"2019","journal-title":"Clin Liver Dis (Hoboken)."},{"key":"10.1016\/j.bmc.2024.117881_b0095","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.7150\/ijbs.92371","article-title":"A novel A2a adenosine receptor inhibitor effectively mitigates hepatic fibrosis in a metabolic dysfunction-associated steatohepatitis mouse model","volume":"20","author":"Park","year":"2024","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.bmc.2024.117881_b0100","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.2174\/156802606777812013","article-title":"Discovery and development of purine-scaffold Hsp90 inhibitors","volume":"6","author":"Chiosis","year":"2006","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.bmc.2024.117881_b0105","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.2174\/156802605774463079","article-title":"Purine derivatives as ligands for A3 adenosine receptors","volume":"5","author":"Joshi","year":"2005","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.bmc.2024.117881_b0110","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1515\/pac-2019-1214","article-title":"Fragment-based approach to novel bioactive purine derivatives","volume":"92","author":"Krasnov","year":"2020","journal-title":"Pure Appl Chem"},{"key":"10.1016\/j.bmc.2024.117881_b0115","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.ejmech.2013.10.006","article-title":"8-(2-Furyl) adenine derivatives as A2A adenosine receptor ligands","volume":"70","author":"Dal Ben","year":"2013","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2024.117881_b0120","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1016\/j.bmc.2014.04.041","article-title":"8-Substituted 2-alkynyl-N9-propargyladenines as A2A adenosine receptor antagonists","volume":"22","author":"Endo","year":"2014","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2024.117881_b0125","doi-asserted-by":"crossref","first-page":"11648","DOI":"10.1021\/acs.jmedchem.2c00462","article-title":"GPCR agonist-to-antagonist conversion: enabling the design of nucleoside functional switches for the A2A adenosine receptor","volume":"65","author":"Shiriaeva","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117881_b0130","doi-asserted-by":"crossref","first-page":"8851","DOI":"10.1016\/j.tet.2009.08.057","article-title":"Linear and convergent approaches to 2-substituted adenosine-5\u2032-N-alkylcarboxamides","volume":"65","author":"Foitzik","year":"2009","journal-title":"Tetrahedron"},{"key":"10.1016\/j.bmc.2024.117881_b0135","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0223-5234(02)01446-0","article-title":"Design, synthesis and structure-activity relationships of a series of 9-substituted adenine derivatives as selective phosphodiesterase type-4 inhibitors","volume":"38","author":"Raboisson","year":"2003","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2024.117881_b0140","doi-asserted-by":"crossref","first-page":"4997","DOI":"10.1039\/C3CC48642G","article-title":"Direct N 9-arylation of purines with aryl halides","volume":"50","author":"Larsen","year":"2014","journal-title":"Chem Commun"},{"key":"10.1016\/j.bmc.2024.117881_b0145","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1021\/ol0608505","article-title":"4,7-Dimethoxy-1,10-phenanthroline: an excellent ligand for the Cu-catalyzed N-arylation of imidazoles","volume":"8","author":"Altman","year":"2006","journal-title":"Org Lett"},{"key":"10.1016\/j.bmc.2024.117881_b0150","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1126\/science.1164772","article-title":"The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist","volume":"322","author":"Jaakola","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.bmc.2024.117881_b0155","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nature10136","article-title":"Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation","volume":"474","author":"Lebon","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2024.117881_b0160","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1152\/physrev.00017.2008","article-title":"Transcription factors in long-term memory and synaptic plasticity","volume":"89","author":"Alberini","year":"2009","journal-title":"Physiol Rev"},{"key":"10.1016\/j.bmc.2024.117881_b0165","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1042\/BJ20131115","article-title":"CREB phosphorylation at Ser133 regulates transcription via distinct mechanisms downstream of cAMP and MAPK signalling","volume":"458","author":"Naqvi","year":"2014","journal-title":"Biochem J"},{"key":"10.1016\/j.bmc.2024.117881_b0170","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3892\/ijmm.2016.2630","article-title":"p-CREB-1 promotes hepatic fibrosis through the transactivation of transforming growth factor-\u03b21 expression in rats","volume":"38","author":"Wang","year":"2016","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.bmc.2024.117881_b0175","doi-asserted-by":"crossref","first-page":"e52977","DOI":"10.15252\/embr.202152977","article-title":"Hypoxia-induced ELF3 promotes tumor angiogenesis through IGF1\/IGF1R","volume":"23","author":"Seo","year":"2022","journal-title":"EMBO Rep"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089624002955?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089624002955?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T01:17:27Z","timestamp":1725931047000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089624002955"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":35,"alternative-id":["S0968089624002955"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2024.117881","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring novel A2AAR antagonists: Design, synthesis, and evaluation of 2,6,9-trisubstituted purine derivatives as promising antifibrotic agents","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2024.117881","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"117881"}}